Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report

Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report

Epidermal growth factor receptor (EGFR) exon 20 insertion is not associated with sensitivity to EGFR tyrosine kinase inhibitors and chemotherapy. Here, we report the case of a 41-year-old man who presented a right lower lobe nodule and mediastinal lymph node enlargement diagnosed as EGFR exon 20 ins...

Full description

Bibliographic Details
Main Authors: Shun Matsuura, Keisuke Morikawa, Yutaro Ito, Namio Kagoo, Tsutomu Kubota, Koshiro Ichijo, Eisuke Mochizuki, Masahiro Uehara, Masanori Harada, Masaru Tsukui, Naoki Koshimizu
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Respiratory Medicine Case Reports
Subjects:
EGFR
Exon 20 insertion
Durvalumab
Non-small-cell lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007120304500

Internet

http://www.sciencedirect.com/science/article/pii/S2213007120304500

Similar Items